Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy

被引:16
|
作者
Xiao, Yuchen [1 ,2 ]
Zhu, Tianchuan [1 ]
Zeng, Qi [3 ]
Tan, Qingqin [1 ]
Jiang, Guanmin [4 ]
Huang, Xi [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Infect & Immun, Guangdong Prov Key Lab Biomed Imaging, Zhuhai 519000, Guangdong, Peoples R China
[2] Southern Marine Sci & Engn Guangdong Lab, Zhuhai 519000, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Oncol, Zhuhai 519000, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Clin Lab, Zhuhai 519000, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
PD-L1; Photothermal ablation; Biomimetic nanoparticles; Tumor microenvironment; Colorectal cancer; RESISTANCE;
D O I
10.1016/j.actbio.2022.11.043
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand pro-grammed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, including colorectal cancer. However, the efficacy of PD-1/PD-L1 inhibitors is limited in some colorec-tal cancers within the immunosuppressive tumor microenvironment (such as when there is a lack of immune cell infiltration). Herein, anti-PD-L1 functionalized biomimetic polydopamine-modified gold nanostar nanoparticles (PDA/GNS@aPD-L1 NPs) were developed for synergistic anti-tumor treatment by combining PD-1/PD-L1 blockade with photothermal ablation. PDA/GNS@aPD-L1 NPs were prepared by encapsulating photothermal nanoparticles (polydopamine-modified gold nanostar, PDA-GNS) with cell membrane isolated from anti-PD-L1 single-chain variable fragment (scFv) over-expressing cells. In ad-dition to disrupting PD-1/PD-L1 immunosuppressive signals, the anti-PD-L1 scFv on the membrane of PDA/GNS@aPD-L1 NPs was conducive to the accumulation of PDA-GNS at tumor sites. Importantly, the tu-mor photothermal ablation induced by PDA-GNS could reverse the immunosuppressive tumor microenvi-ronment, thereby further improving the efficiency of PD-1/PD-L1 blockade therapy. In this study, the syn-thetized PDA/GNS@aPD-L1 NPs exhibited good biocompatibility, efficient photothermal conversion ability, and enhanced tumor-targeting ability. In vivo studies revealed that a PDA/GNS@aPD-L1 NP-based thera-peutic strategy significantly inhibited tumor growth, and prolonged overall survival by further promot-ing the maturation of dendritic cells (DCs), increasing the infiltration of CD8 + T cells, and decreasing the number of immunosuppressive cells (such as regulatory T cells and myeloid-derived suppressive cells). Collectively, the developed PDA/GNS@aPD-L1 NP-based therapeutic strategy combines PD-1/PD-L1 block-ade with photothermal ablation, which could remodel the tumor microenvironment for effective clinical colorectal cancer therapy.Statement of significance Immunosuppressive tumor microenvironment is the main challenge facing programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) blockade therapy. By encapsulating photothermal nanopar-ticles (polydopamine-modified gold nanostar, PDA-GNS) with cell membrane over-expressing anti-PD -L1 single-chain variable fragment, we constructed anti-PD-L1 functionalized biomimetic nanoparticles (PDA/GNS@aPD-L1 NPs). By specific binding to the PD-L1 present on tumor cells, PDA/GNS@aPD-L1 NPs could disrupt PD-1/PD-L1 immunosuppression signaling, and effectively deliver PDA-GNS targeting to tu-mor sites. Additionally, PDA-GNS-mediated local photothermal ablation of tumors promoted the release of tumor-associated antigens and thus activated anti-tumor immune responses. Meanwhile, hyperthermia facilitates immune cell infiltration by increasing tumor vascular permeability. Therefore, PDA/GNS@aPD-L1 NPs could sensitize tumors to PD-1/PD-L1 blockade therapy by remodeling the immunosuppressive tumor microenvironment, which provides a new strategy for tumor treatment.(c) 2022 The Authors. Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:451 / 466
页数:16
相关论文
共 50 条
  • [11] Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease
    Goto, Hiroyuki
    Sugita, Kazunari
    Yamamoto, Osamu
    INDIAN JOURNAL OF DERMATOLOGY, 2021, 66 (02) : 169 - 173
  • [12] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway
    Wang, Tianyu
    Wu, Xiaoxing
    Guo, Changying
    Zhang, Kuojun
    Xu, Jinyi
    Li, Zheng
    Jiang, Sheng
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (04) : 1715 - 1730
  • [13] OCULAR ADVERSE EVENTS ASSOCIATED WITH PROGRAMMED DEATH-1 AND PROGRAMMED DEATH LIGAND-1 IMMUNOTHERAPY
    Young, LeAnne
    Finnigan, Shanda
    Streicher, Howard
    Chen, Helen
    Murray, James
    Sen, H. Nida
    Sharon, Elad
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A386 - A387
  • [14] Different Programmed Death-1/Programmed Death-Ligand 1 Expression Patterns for Each Pediatric Lymphoma Subtype
    Tamura, A.
    Yoshida, M.
    Yamamoto, N.
    Nino, N.
    Nakatani, N.
    Ichikawa, T.
    Nakamura, S.
    Saito, A.
    Kozaki, A.
    Kishimoto, K.
    Ishida, T.
    Mori, T.
    Hasegawa, D.
    Kosaka, Y.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S271 - S271
  • [15] Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
    Fujiwara, Mai
    Anstadt, Emily J.
    Clark, Robert B.
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [16] Role of Programmed Death-Ligand 1 in Cancer
    Link, Tina
    Dilip, Megha
    Caruso, Olivia
    Chang, Margaret
    Kona, Abhinav
    Liu, Jesse
    Nathan, Ajay
    Singh, Anita
    Thomas-Wilkinson, Shiloh
    FASEB JOURNAL, 2019, 33
  • [17] Advances in pancreatic cancer immunotherapy for targeting programmed death-ligand 1
    Jiang, Haitao
    Fan, Xiaoxiang
    ASIAN JOURNAL OF SURGERY, 2023, 46 (06) : 2378 - 2379
  • [18] Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis
    Zhang, Qiang
    Qi, Zhijiang
    Bo-Liu
    Li, Chun-Sheng
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [19] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
    Arbour, Kathryn C.
    Mezquita, Laura
    Long, Niamh
    Rizvi, Hira
    Auclin, Edouard
    Ni, Andy
    Martinez-Bernal, Gala
    Ferrara, Roberto
    Lai, W. Victoria
    Hendriks, Lizza E. L.
    Sabari, Joshua K.
    Caramella, Caroline
    Plodkowski, Andrew J.
    Halpenny, Darragh
    Chaft, Jamie E.
    Planchard, David
    Riely, Gregory J.
    Besse, Benjamin
    Hellmann, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2872 - +
  • [20] Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses
    Yoon, Jihoon G.
    Kim, Min Hwan
    Jang, Mi
    Kim, Hoguen
    Hwang, Ho Kyoung
    Kang, Chang Moo
    Lee, Woo Jung
    Kang, Beodeul
    Lee, Choong-kun
    Lee, Min Goo
    Chung, Hyun Cheol
    Choi, Hye Jin
    Park, Young Nyun
    HEPATOLOGY, 2021, 74 (04) : 1914 - 1931